Werewolf Therapeutics' revenue performance is uncertain, and...

Werewolf Therapeutics' revenue performance is uncertain, and it's P/S ratio is low compared to the biotech industry due to potential shrink in revenues. Its low P/S ratio is justified given other companies' revenue growth forecasts, indicating no significant share price rise.